Obesity
Conditions
Brief summary
The aim of this study is to investigate the effect of the treatment with the GLP-1 Analogon Liraglutide on the lipid metabolism an inflammation in adipose tissue.
Detailed description
The aim of this study is to investigate the effect of the treatment with the GLP-1 Analogon Liraglutide on the lipid metabolism an inflammation in adipose tissue. As GLP-1 is presumed to improve insulin sensitivity and associated parameters the investigators hypothesize that this might be due to changes in lipid metabolism which might be involved in the regulation of insulin sensitivity. Therefore the investigators intend to investigate changes of metabolic pathways before and after treatment with the GLP-1 analog liraglutide that could play a crucial role in pathogenesis as well as regulation of insulin sensitivity and atherogenic dyslipidemia such as: de novo lipogenesis and reverse cholesterol transport
Interventions
DRUGGLP-1 (Liraglutide)
GLP-1 Analogon
DRUGPlacebo
Placebo
Sponsors
Universitätsklinikum Hamburg-Eppendorf
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to 77 Years
Healthy volunteers
No
Inclusion criteria
* BMI 35-55 Kg/m2 * Fasting Blood glucose \>140mg/dl * Planned bariatric surgery * Diabetic Medication (Metformin, Sulfonylurea, Insuline)
Exclusion criteria
* Known hypersensitivity against Liraglutid * Pretreatment DPP-4 Inhibitors or GLP-1 Analogue the last 3 months * HbA1c \>10%
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| weight reduction | 4 years | to compare body weight with type 2 Diabetes scheduled for weight loss surgery after 8 weeks of preoperative treatment with either placebo or liragludite |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GLP-1 Levels | 4 years | Measurement of GLP-1 levels during the defined period |
Countries
Germany
Outcome results
None listed